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Abstract
Background: The optimal timing of surgery in relation to chemoradiation is still controversial. Retrospective analysis
has demonstrated in the recent decades that the regression of adenocarcinoma can be slow and not complete
until after several months. More recently, increasing pathologic Complete Response rates have been demonstrated
to be correlated with longer time interval. The purpose of the trial is to demonstrate if delayed timing of surgery
after neoadjuvant chemoradiotherapy actually affects pathologic Complete Response and reflects on disease-free
survival and overall survival rather than standard timing.
Methods: The trial is a multicenter, prospective, randomized controlled, unblinded, parallel-group trial comparing
standard and delayed surgery after neoadjuvant chemoradiotherapy for the curative treatment of rectal cancer.
Three-hundred and forty patients will be randomized on an equal basis to either robotic-assisted/standard
laparoscopic rectal cancer surgery after 8 weeks or robotic-assisted/standard laparoscopic rectal cancer surgery after
12 weeks.
Discussion: To date, it is well-know that pathologic Complete Response is associated with excellent prognosis and
an overall survival of 90%. In the Lyon trial the rate of pCR or near pathologic Complete Response increased from
10.3 to 26% and in retrospective studies the increase rate was about 23–30%. These results may be explained on
the relationship between radiation therapy and tumor regression: DNA damage occurs during irradiation, but
cellular lysis occurs within the next weeks. Study results, whether confirmed that performing surgery after 12 weeks
from neoadjuvant treatment is advantageous from a technical and oncological point of view, may change the
current pathway of the treatment in those patient suffering from rectal cancer.
Trial registration: ClinicalTrials.gov NCT3465982.
Keywords: Radiation therapy, Minimally invasive surgery, Rectal cancer, Neoadjuvant treatment, Robotic surgery,
TaTME, Timing to surgery,
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Background
Chemoradiotherapy is a well-known risk reducing treat-
ment of local recurrence in the treatment of rectal can-
cer, followed by total mesorectal excision (TME). In low
rectal tumors, surgery alone has the 30% overall survival
and a local recurrence rate of about 55–65%, with a
disease-free survival of 30–35% [1]. Preoperative admin-
istration of fluorouracil-based chemotherapy improved
local recurrence rates to 7% [2]. The optimal timing of
surgery in relation to chemoradiation is still controver-
sial. Retrospective analysis has demonstrated in the re-
cent decades that the regression of adenocarcinoma can
be slow and not complete until after several months [3].
More recently, increasing pCR (pathological complete
response) rates have been demonstrated to be correlated
with longer time interval [4–6]. Conversely, several re-
ports have shown no impact of the interval after chemo-
radiation on pCR and technical performance [7, 8]. In
the Lyon trial the rate of pCR or near pCR increased
from 10.3 to 26% [9] and in retrospective studies the in-
crease rate was about 23–30%. These results may be ex-
plained on the relationship between radiation therapy
and tumor regression: DNA (DeoxyriboNucleic Acid)
damage occurs during irradiation, but cellular lysis oc-
curs within the next weeks [10]. A recent pilot study on
comparison of resonance imaging and histopathological
responses at two times, has suggested that volume re-
duction and down-staging occur between week 9 and
week 14 after neoadjuvant treatment, with a 23% pCR
rate at longer time [11]. In the Stockholm III trial, a sig-
nificantly lower frequency of postoperative complica-
tions was reported, even though not described in the
other studies where morbidity and complications were
the same. All of these studies, however, presented some
biases, such as absence of randomization, the choice of
surgical timing made arguably by the surgeon, tumor
size and response to RCT (radiochemotherapy), different
cut-off period and a limited number of recruited pa-
tients, that may have negatively or positively influenced
these results [12, 13]. Delaying surgery with the aim to
detect excellent responders for organ preservation, even-
tually, may be legitimate, even though the start of adju-
vant therapy, whose advantage in pretreated rectal
cancer patients is still controversial, would be delayed,
and this may negatively affect survival [14, 15]. A recent
meta-analysis on thirteen reports has been published,
showing rates of 14 and 20% in the shorter and longer
group, respectively. This meta-analysis has some biases:
the pCR correlation with surgical delay could not be ad-
justed in a multivariate analysis with other clinico-
pathological variables, the outcome (DFS and OS) of
pCR, even if likely better than those without pCR as lit-
erature demonstrates, could not be directly assessed due
to lack of individual patient data, the number of patients
operated on in the delayed group could have been
chosen using a surgical decision, different time intervals
were grouped all together, no randomized trial were in-
cluded in the meta-analysis, and the relevance of the re-
ports included in was assessed by NOS scale
(Newcastle–Ottawa scale), that is quite arbitrary, several
reports on observation, demonstrating a higher percent-
age of pCR, were not included, but it is quite relevant to
consider also these studies. TiMiSNAR has been devel-
oped to improve and define previous results from retro-
spective and review analyses.
Methods/design
The trial is a multicenter, prospective, randomized con-
trolled, unblinded, parallel-group trial comparing stand-
ard and delayed surgery after neoadjuvant
chemoradiotherapy for the curative treatment of rectal
cancer. Three-hundred and forty patients will be ran-
domized on an equal basis to either robotic-assisted/
standard laparoscopic rectal cancer surgery after 8 weeks
or robotic-assisted/standard laparoscopic rectal cancer
surgery after 12 weeks (Fig. 1). Eight weeks are the
current standard interval to surgery after neodjuvant
treatment, while 12 weeks represent the “minimum” lon-
ger time interval to determine further tumor modifica-
tions and the “a priori” choice to avoid hypothetic
surgical detrimental effect (postoperative complications
related to radiation therapy). The recruiting interval will
be of 5 years and the follow-up period will end 5 years
after the last patient is randomized.
The trial has been held in Alessandria at SS. Anto-
nio e Biagio e Cesare Arrigo Community Hospital,
Italy and in others National Academic and not-
Academic Centers, list of which is available at https://
www.timisnar.it.
The Primary Endpoint is pCR; secondary endpoints
are: DFS (disease-free survival), OS (overall survival),
postoperative complications (Clavien-Dindo classifica-
tion), reintervention, late complications (Clavien-Dindo
classification), radiation toxicity, chemotherapy toxicity,
QoL (quality of life), Functional status.
Inclusion Criteria are: age > 18 years, cT3/4 N0/+M0
confirmed on CT-scan (Computed Tomography Scan),
MRI (Magnetic Resonance Imaging - stratification for
T3a-b-c-d), tumor starting from the distal or medium
rectum (even those crossing the peritoneal reflection at
distal margin, within 15 cm from the anal margin),
histologically-proven adenocarcinoma of the rectum, eli-
gible for a resective surgery with TME (low anterior re-
section, intersphyncteric resection, abdominoperineal
resection), eligible for resection by minimally-invasive
surgery (standard or robotic-assisted laparoscopic pro-
cedure, all robotic systems will be accepted), eligible for
chemoradiation treatment, able to give written informed
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consent, capable of completing required questionnaires at
time of consent (provided questionnaires are available in a
language spoke fluently by the participant).
Main exclusion Criteria are: metastatic disease, squa-
mous carcinoma of the anal canal, unable to complete
neoadjuvant treatment.
Patients will be randomized on a 1:1 basis to receive
minimally-invasive rectal cancer surgery 8 or 12 weeks
after neoadjuvant treatment and will be allocated a
unique trial number.
Participants will be randomized using Sealed Envelope
Ltd. 2017 Online Simple randomization service. Alloca-
tion concealment will be ensured, as the service will not
release the randomization code until the patient has
been recruited into the trial, which takes place after all
baseline measurements have been completed.
An informed consent to participate has been prepared
and will be obtained by all the participants.
All patients who give consent for participation and who
fulfil the inclusion criteria will be randomized.
Randomization will be requested by the staff member re-
sponsible for recruitment and clinical interviews from all
participating centers. Due to the nature of the intervention
neither participants nor staff can be blinded to allocation,
but are strongly inculcated not to disclose the allocation
status of the participant at the follow up assessments.
Fig. 1 Flow chart of TiMiSNAR Trial
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All the involved centers have to respect the following
criteria: site able to perform robotic-assisted and stand-
ard laparoscopic rectal cancer surgery and TaTME
(transanal total mesorectal excision); site able to provide
standard neoadjuvant treatment, both chemo and radi-
ation therapy; predicted capability to recruit a minimum
of 15 patients per year to the trial.
Neoadjuvant treatment consists in long course radi-
ation therapy with IMRT (Intensity Modulated Radio-
Therapy – 50-54 Gy in 25–28 fractions; an optional
boost is suggested) associated to concomitant chemo-
therapy treatment (Capecitabine 825 mg /m2/ twice daily
during radiation therapy).
Several studies have compared IMRT of rectal cancer
to 3D Conformal Radiotherapy. Although results from
comparative randomized clinical trial are not available
yet, IMRT is usually associated with less dose to organ
at risk, such as urinary bladder, small bowel and anal
sphincters (in selected cases). This is translated into bet-
ter clinical outcomes, in terms of gastrointestinal tox-
icity, genitourinary toxicity and skin side effects [16–20].
Restaging and treatment-efficacy assessment after
Neoadjuvant therapy
The MERCURY study group has developed an MRI-
based tumor regression grading (ymrTRG) system by ap-
plying the principles of histopathological tumor regres-
sion grade (ypTRG) [21].
Recently, a pilot study from UK has defined two
groups of patients divided into favourable vs unfavour-
able responders based on the following three factors:
 ymrT
 ymrTRG
 Change in volume
ymrT is based on the interpretation of local extent of
persistent tumor signal intensity relative to the layers of
bowel wall on T2-weighted images. Tumor response is
evaluated as either replacement of tumor signal by low
signal intensity fibrosis (dark stroma) or the develop-
ment of high signal intensity mucin pools, that are not
considered to be tumor.
ymrTRG is based on principles similar to the patho-
logical ypTRG system described by Dworak and subse-
quently modified by Mandard.
Change in volume, better defined as percentage vol-
ume reduction is calculated multiplying tumor length,
width and height, using the following formula:
100 Volume at baselineð Þ− Volume post−CRTð Þf g= Volume at baselineð Þ
Time interval to surgery in this trial are 8 weeks and
12 weeks after treatment, that are the standard and the
expected “minimum” longer time interval to determine
further tumor modifications. Post-treatment staging for
evaluation of postneoadjuvant treatment response, even-
tually, will depend on MRI evaluation at week 7 for pa-
tients in both the two arms; a MRI evaluation will be
repeated at week 11 for patients randomized in the de-
layed arm.
A Thoraco-abdominal CT-Scan with and without con-
trast enhancement will be performed at week 6 after
neoadjuvant surgery, for restaging of potential dissemi-
nated disease.
All MRI exams are collected and sent to the Promot-
ing Center for final revision by a well-trained Pelvic MRI
expert radiologist. Every participating center must fill in
a structured MRI form according to the fac-simile pro-
vided by the ESGAR (European Society of Gastrointes-
tinal and Abdominal Radiology) [22].
Surgery
Minimally-invasive mesorectal resection is required:
both robotic or standard laparoscopic approach or
TaTME will be accepted, in accordance with each sur-
geon’s usual practice. The specifics of each operation
will be at the discretion of the operating surgeon (e.g.
port-site placement, mobilization of the splenic flexure,
inferior mesenteric artery/vein division, high versus low
vascular division etc.), as well as the decision to convert
to an open operation. Conversion to open operation is
defined as the use of a laparotomy wound for any part of
the mesorectal dissection. All participating centers are
allowed and suggested to use Indocyanine Green test
(ICG), wherever available, but it is not mandatory. Sev-
eral studies have shown that ICG test could reduce anas-
tomotic leakage and thus postoperative complications,
that are important in light of the secondary endpoints. A
recent systematic review and meta-analysis by Blanco-
Colino et al. has shown that ICG fluorescence imaging
seems to reduce AL rates following colorectal surgery
for cancer [23].
Post-operative care and follow up
Post-operative care and follow up will be as per institu-
tional protocol, but patients must be reviewed at 30 days,
and 6 months post-operatively at a minimum. Any fur-
ther visits will be according to local standard clinical
practice. All patients will be followed up as per protocol
until 5 years after the last patient has been randomized.
Statistical evaluation
Sample size
The primary endpoint is the pCR rate. Based on the
published results from prospective studies on delayed
time interval or observation only and on retrospective
study for standard time interval, we assume that the
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mean rate of pCR in the standard treatment is about
15%, while the mean pCR rate in the observation treat-
ment or longer time interval is 30%. To determine this
difference, 270 patients are required, using a two-group
continuity corrected χ2 test of equal proportions, assum-
ing an α error of 4.9% and a power of 80% (MedCalc
Version 17.9.7); an interim analysis on efficacy will be
performed when half of events will be observed. The
conservative Haybittle-Peto [24] boundary will be used
as a stopping guidance in order to perform the final ana-
lysis at the significance level of 4.9%, two sides. Consid-
ering results from the pilot study reported on section 1,
the percentage of unfavourable patients is 20%
(favourable MRI tumor regression grade is defined as
grades 1, 2 and 3; unfavourable MRI regression as grades
4 and 5). In addition, a meta-analysis on results from
five randomized European clinical trials for locally ad-
vanced rectal cancer, has confirmed this rate of “poor”
responders subgroup, identified by having no pCR and
no DFS within 2 years [25]. In computing the sample
size, we assume that the percentage of missing data will
be 5%. A total of 340 patients, 170 for each arm, is
intended to be enrolled, eventually. Patients will be ran-
domized on a 1:1 basis to receive minimally-invasive rec-
tal cancer surgery 8 or 12 weeks after neoadjuvant
treatment and will be allocated a unique trial number. A
computer-generated software with block randomization
criteria will be used to ensure treatment groups are well-
balanced for timing of surgery. All enrolled patients’ data
will be registered in a prospective electronic database
(ACCESS, MICROSOFT OFFICE Professional Plus
2010, regular licensed).
All data will be entered by means of case report forms.
Original study forms will be entered and kept on file at
the Coordinator site (SS. Antonio e Biagio e Cesare
Arrigo Hospital). When a form is selected, the partici-
pating site staff will pull that form, copy it, and sent the
copy to the DCC (Data Coordinating Center) for re-
entry. Participant files are to be stored in numerical
order and stored in a secure and accessible place and
manner. Participant files will be maintained in storage
for a period of 5 years after completion of the study.
The DCC will send monthly email reports with infor-
mation on missing data, missing forms, and missing
visits. Personnel at the Core Coordinating Center and
the Participating Sites should review these reports for
accuracy and report any discrepancies to the DCC.
Statistical analysis
All efficacy outcomes will be assessed in the intention-
to-treat population, which includes all enrolled patients
who did not violate the eligibility criteria. pCR, OS and
DFS will be assessed from the time of treatment alloca-
tion to local progression, death or disease progression.
Patients who will not die and will not experience local of
distant disease progression at the date of study cutoff
will be censored at the last available information on
status.
Time-to-event data will be analyzed by the Kaplan-
Meier method and compared with the log-rank test. Cox
proportional hazards model will be used to adjust the
treatment effect for baseline prognostic factors.
Serious adverse events reporting (SAE)
Any SAE considered to be reasonably related to the in-
vestigational treatment or study participation, have to be
promptly notified.
This must be done by email within 24 h of the initial
observation of the event. The principal investigator will
decide if these events are related to the trial treatment
(i.e. unrelated, likely related, and not assessable) and the
decision will be recorded on the Serious Adverse Event
form, if necessary with the reasoning of the principal
investigator.
The investigator is obligated to assess the relationship
between investigational treatment and the occurrence of
each AE/SAE. A “reasonable possibility” is meant to con-
vey that there are facts/evidence or arguments to suggest
a causal relationship, rather than a relationship cannot
be ruled out. The investigator will use clinical judgement
to determine the relationship. Alternative causes, such
as natural history of the underlying diseases, concomi-
tant therapy, other risk factors, and the temporal rela-
tionship of the event to the investigational product will
be considered and investigated.
End of the study
The end of the study is defined as 5 years after the date
that the last patient has been randomized to the trial.
Research ethics approval
The protocol, site-specific informed consent forms, par-
ticipant education and recruitment materials, and other
requested documents — and any subsequent modifica-
tions — also has been reviewed and approved by SS.
Antonio e Biagio e Cesare Arrigo Hospital Ethical Com-
mittee on 31 May 2018.
Discussion
To date, it is well-know that pCR is associated with ex-
cellent prognosis and an overall survival of 90% [1]. In
the Lyon trial the rate of pCR or near pCR increased
from 10.3 to 26% [2] and in retrospective studies the in-
crease rate was about 23–30%. These results may be ex-
plained on the relationship between radiation therapy
and tumor regression: DNA damage occurs during ir-
radiation, but cellular lysis occurs within the next weeks
[3]. In the Stockholm III trial, a significantly lower
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frequency of postoperative complications was reported,
even though not described in the other studies where
morbidity and complications were the same.
There are several audiences for this trial: Oncologists,
Surgeons, Radiation oncologists, Patients and the public,
Academia, General Practitioners.
Another crucial point of the trial is the use of a struc-
tured MRI report, as recommended by the European So-
ciety of Gastrointestinal and Abdominal Radiology
(ESGAR) [22], for primary staging and for restaging after
neoadjuvant treatment. One of the goals of the trial is to
determine whether MRI can specifically depict cancer
local diffusion and predict downstaging and be used as a
good prognostic instrument. High quality MRI, indeed,
allows further subclassification of cT3, which is recom-
mended by European Society for Medical Oncology
(ESMO) guidelines and it is useful in stratifying and
selecting patients with indication to neoadjuvant treat-
ment before surgery.
In summary, the optimal interval between adjuvant
chemoradiation and surgery may give the opportunity to
optimize patients, initiate an individualized and “tar-
geted” treatment, and favor organ preservation.
TiMiSNAR (NCT3465982 – https://www.timisnar.it)
results, whether confirmed that performing surgery after
12 weeks from neoadjuvant treatment is advantageous
from a technical and oncological point of view, may
change the current pathway of the treatment in those
patient suffering from rectal cancer.
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